Key Decisions and Financial Results

The Board of Directors of Suraksha Diagnostic Limited at its meeting held on 12 August 2026 (commenced at 3:00 PM IST, concluded at 4:30 PM IST) approved the following:

1. Financial Results Approval

  • Approved unaudited standalone and consolidated financial results for the quarter ended 30 June 2026
  • Results submitted pursuant to Regulation 33 of SEBI Listing Regulations
  • Statutory Auditors MSKA & Associates LLP issued unmodified limited review reports for both standalone and consolidated results

Standalone Financial Results (₹ in lakhs)

| Particulars | Q1 FY27 (30 Jun 2026) | Q4 FY26 (31 Mar 2026) | Q1 FY26 (30 Jun 2025) | FY26 (31 Mar 2026) |

| Revenue from operations | 8,408.62 | 7,855.59 | 7,027.90 | 30,067.91 |

| Other income | 156.41 | 130.28 | 109.57 | 435.23 |

| Total Income | 8,565.03 | 7,985.87 | 7,137.47 | 30,503.14 |

| Profit before tax | 1,621.24 | 1,055.72 | 1,312.08 | 4,721.51 |

| Total tax expense | 363.04 | 384.80 | 327.21 | 1,315.29 |

| Profit for the period | 1,258.20 | 670.92 | 984.87 | 3,406.22 |

| Basic EPS (₹) | 2.42 | 1.29 | 1.89 | 6.54 |

| Diluted EPS (₹) | 2.42 | 1.29 | 1.89 | 6.54 |

Consolidated Financial Results (₹ in lakhs)

| Particulars | Q1 FY27 (30 Jun 2026) | Q4 FY26 (31 Mar 2026) | Q1 FY26 (30 Jun 2025) | FY26 (31 Mar 2026) |

| Revenue from operations | 8,764.54 | 8,141.15 | 7,258.63 | 31,041.41 |

| Other income | 108.77 | 78.54 | 90.57 | 316.41 |

| Total Income | 8,873.31 | 8,219.69 | 7,349.20 | 31,357.82 |

| Profit before tax | 1,652.58 | 998.09 | 1,246.87 | 4,455.68 |

| Total tax expense | 368.04 | 382.17 | 329.36 | 1,315.43 |

| Profit for the period | 1,284.54 | 615.92 | 917.51 | 3,140.25 |

| Basic EPS (₹) | 2.50 | 1.21 | 1.80 | 6.18 |

| Diluted EPS (₹) | 2.50 | 1.21 | 1.80 | 6.18 |

2. CFO Appointment

  • Appointed Mr. Dinesh Gupta as Chief Financial Officer of the Company effective 24 August 2026
  • He will also act as Group Chief Financial Officer
  • Appointment based on recommendations of Nomination and Remuneration Committee and Audit Committee

Profile of Mr. Dinesh Gupta:

  • Seasoned finance professional with over 14 years of experience
  • Bachelor's degree in Commerce from University of Calcutta
  • Member of Institute of Chartered Accountants of India since 2011
  • Previously served as Assistant General Manager at Saranyu Power Trading Private Limited (India Power Corporation Limited group company)
  • Previous roles include Assistant Manager at Genpact (Kolkata), and Analyst at Maersk Global Services Limited (Pune) and Gupta Deals and Merchandise Private Limited

3. Annual General Meeting

  • Approved revised notice convening the 21st Annual General Meeting for FY 2025-26
  • AGM to be held on Tuesday, 22 September 2026 through video conferencing/audio-visual means

4. Dividend Record Date

  • Fixed Tuesday, 15 September 2026 as Record Date for determining shareholder entitlement to dividend for FY ended 31 March 2026
  • Dividend payment subject to shareholder approval at the 21st AGM
  • Dividend to be paid within statutory period prescribed under Companies Act, 2013

Subsidiary Information and Contingency

The consolidated results include the following subsidiaries:

  • Suraksha Speciality LLP (Subsidiary)
  • Suraksha Radiology Private Limited (Subsidiary)
  • Suraksha Advanced Radiology Private Limited (Subsidiary)
  • Asian Institute of Immunology and Rheumatology LLP (Subsidiary)
  • Fetomat Wellness Private Limited (Subsidiary)
  • Suraksha Salvia LLP (Step-down subsidiary)

Key Subsidiary Disclosure:

  • A dispute with Government of Meghalaya (public partner) in step-down subsidiary Suraksha Salvia LLP has resulted in operational losses
  • Recoverability of Company's investments, loans advanced to subsidiary, and trade receivables aggregating ₹393.67 lakhs as at 30 June 2026 is under assessment
  • Management has initiated arbitration proceedings through subsidiary
  • Next hearing scheduled on 21 August 2026 at Hon'ble High Court of Meghalaya
  • Management believes arbitration outcome will be favorable
  • However, provided ₹81.16 lakhs provision on said balances on prudent basis considering dispute is subjudice

Auditor's Review

MSKA & Associates LLP conducted limited review of both standalone and consolidated financial results and issued unmodified conclusions. For consolidated results, the auditor relied on review reports of other auditors for six subsidiaries whose interim financial results reflected:

  • Total revenues: ₹428.70 lakhs (before consolidation adjustments)
  • Total net loss after tax: ₹117.84 lakhs (before consolidation adjustments)
  • Total comprehensive income: ₹(117.84) lakhs (before consolidation adjustments)

Additional Information

  • Financial results prepared in accordance with Ind AS 34 'Interim Financial Reporting'
  • Figures for quarter ended 31 March 2026 are balancing figures between audited full-year figures and published nine-month figures ended 31 December 2025
  • Company primarily engaged in diagnostic centers for pathology and radiology services
  • No separate reportable segments as per Ind AS 108